Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in Pseudomonas aeruginosa
dc.rights.license | open | en_US |
dc.contributor.author | POIREL, Laurent | |
dc.contributor.author | ORTIZ DE LA ROSA, José-Manuel | |
dc.contributor.author | KIEFFER, Nicolas | |
hal.structure.identifier | Microbiologie Fondamentale et Pathogénicité [MFP] | |
dc.contributor.author | DUBOIS, Veronique | |
hal.structure.identifier | Microbiologie Fondamentale et Pathogénicité [MFP] | |
dc.contributor.author | JAYOL, Aurelie | |
dc.contributor.author | NORDMANN, Patrice | |
dc.date.accessioned | 2023-12-01T10:50:03Z | |
dc.date.available | 2023-12-01T10:50:03Z | |
dc.date.issued | 2019-01-01 | |
dc.identifier.issn | 1098-6596 | en_US |
dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/186300 | |
dc.description.abstractEn | A clinical isolate resistant to all β-lactams, including ceftolozane-tazobactam and carbapenems, was recovered. It belonged to sequence type 235 and produced the extended-spectrum β-lactamase (ESBL) GES-6 differing from GES-1 by two amino acid substitutions (E104K and G170S). GES-6 possessed an increased hydrolytic activity toward carbapenems and to ceftolozane and a decreased susceptibility to β-lactamase inhibitors compared to GES-1, except for avibactam. We show here that resistance to ceftolozane-tazobactam may occur through acquisition of a specific ESBL in but that ceftazidime-avibactam combination remains an effective alternative. | |
dc.language.iso | EN | en_US |
dc.rights | Attribution 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
dc.subject.en | Amino Acid Substitution | |
dc.subject.en | Anti-Bacterial Agents | |
dc.subject.en | Azabicyclo Compounds | |
dc.subject.en | Carbapenems | |
dc.subject.en | Ceftazidime | |
dc.subject.en | Cephalosporins | |
dc.subject.en | Drug Combinations | |
dc.subject.en | Gene Expression | |
dc.subject.en | Humans | |
dc.subject.en | Microbial Sensitivity Tests | |
dc.subject.en | Pseudomonas Infections | |
dc.subject.en | Pseudomonas aeruginosa | |
dc.subject.en | Tazobactam | |
dc.subject.en | beta-Lactam Resistance | |
dc.subject.en | beta-Lactamases | |
dc.title.en | Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in Pseudomonas aeruginosa | |
dc.title.alternative | Antimicrob Agents Chemother | en_US |
dc.type | Article de revue | en_US |
dc.identifier.doi | 10.1128/AAC.01809-18 | en_US |
dc.subject.hal | Sciences du Vivant [q-bio]/Microbiologie et Parasitologie | en_US |
dc.identifier.pubmed | 30323045 | en_US |
bordeaux.journal | Antimicrobial Agents and Chemotherapy | en_US |
bordeaux.volume | 63 | en_US |
bordeaux.hal.laboratories | MFP (Laboratoire Microbiologie Fondamentale et Pathogénicité) - UMR 5234 | en_US |
bordeaux.issue | 1 | en_US |
bordeaux.institution | CNRS | en_US |
bordeaux.peerReviewed | oui | en_US |
bordeaux.inpress | non | en_US |
bordeaux.import.source | pubmed | |
hal.identifier | hal-04317650 | |
hal.version | 1 | |
hal.date.transferred | 2023-12-01T10:50:05Z | |
hal.popular | non | en_US |
hal.audience | Internationale | en_US |
hal.export | true | |
workflow.import.source | pubmed | |
dc.rights.cc | Pas de Licence CC | en_US |
bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Antimicrobial%20Agents%20and%20Chemotherapy&rft.date=2019-01-01&rft.volume=63&rft.issue=1&rft.eissn=1098-6596&rft.issn=1098-6596&rft.au=POIREL,%20Laurent&ORTIZ%20DE%20LA%20ROSA,%20Jos%C3%A9-Manuel&KIEFFER,%20Nicolas&DUBOIS,%20Veronique&JAYOL,%20Aurelie&rft.genre=article |